Cargando…
A case of adenomyosis with leiomyoma that was effectively treated with relugolix and kamishoyosan add-on therapy
BACKGROUND: Recently, relugolix, an oral gonadotropin-releasing hormone receptor antagonist, has been considered an effective therapy for leiomyoma based on a phase 3 study in Japanese women. Leiomyoma combined with severe adenomyosis occasionally occurs in perimenopausal women; however, little info...
Autores principales: | Sasamori, Yukifumi, Takehara, Kohei, Terashima, Tsuyoshi, Onodera, Takako, Yatsuki, Keita, Nakagawa, Ippei, Takahashi, Yuko, Nishida, Haruka, Ichinose, Takayuki, Hiraike, Haruko, Nagasaka, Kazunori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375059/ https://www.ncbi.nlm.nih.gov/pubmed/34412607 http://dx.doi.org/10.1186/s12905-021-01442-x |
Ejemplares similares
-
Chlamydia Peritonitis Mimicking Juvenile Carcinomatous Peritonitis Diagnosed by Exploratory Laparoscopy: A Case Report
por: Nishida, Haruka, et al.
Publicado: (2023) -
The TGF-β/UCHL5/Smad2 Axis Contributes to the Pathogenesis of Placenta Accreta
por: Hashimoto, Kei, et al.
Publicado: (2023) -
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
por: Al-Hendy, Ayman, et al.
Publicado: (2022) -
Characteristics of submucosal leiomyomas that could cause severe hemorrhage with relugolix: an observational study
por: Wada, Yoshimitsu, et al.
Publicado: (2023) -
Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial
por: Hoshiai, Hiroshi, et al.
Publicado: (2021)